journal article·2021-02Open access

Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells

Antonio Astorga-Gamaza, Michele Vitali, Mireya L. Borrajo, Rosa Suárez-López, Carlos Jaime, Neus Bastus, Carla Serra-Peinado, Laura Luque-Ballesteros, Oscar Blanch-Lombarte, Julia G. Prado, Juan Lorente, Felix Pumarola, Marc Pellicer, Vicenç Falcó, Meritxell Genescà, Víctor Puntes, Maria J. Buzon

Nano Today· Volume 36

Abstract

HIV represents a persistent infection which negatively alters the immune system. New tools to reinvigorate different immune cell populations to impact HIV are needed. Herein, a novel nanotool for the specific enhancement of the natural killer (NK) immune response towards HIV-infected T-cells has been developed. Bispecific Au nanoparticles (BiAb-AuNPs), dually conjugated with IgG anti-HIVgp120 and IgG anti-human CD16 antibodies, were generated by a new controlled, linker-free and cooperative conjugation method promoting the ordered distribution and segregation of antibodies in domains. The cooperatively-adsorbed antibodies fully retained the capabilities to recognize their cognate antigen and were able to significantly enhance cell-to-cell contact between HIV-expressing cells and NK cells. As a consequence, the BiAb-AuNPs triggered a potent cytotoxic response against HIV-infected cells in blood and human tonsil explants. Remarkably, the BiAb-AuNPs were able to significantly reduce latent HIV infection after viral reactivation in a primary cell model of HIV latency. This novel molecularly-targeted strategy using a bispecific nanotool to enhance the immune system represents a new approximation with potential applications beyond HIV.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: HIV Research and Treatment · Immune Cell Function and Interaction · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (82)

Show source-provided references
1. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection10.1016/j.coi.2016.02.006 ↗
2. Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys10.1038/nm.4421 ↗
3. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes10.1084/jem.20070695 ↗
4. Control of the HIV-1 DNA reservoir is associated in vivo and in vitro with NKp46/NKp30 (CD335 CD337) inducibility and interferon gamma production by transcriptionally unique NK cells10.1128/JVI.00647-17 ↗
5. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy10.1073/pnas.94.24.13193 ↗
6. NK cell exhaustion10.3389/fimmu.2017.00760 ↗
7. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy10.1172/JCI10565 ↗
8. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy10.1038/nnano.2017.69 ↗
9. Nanoparticle-mediated cellular response is size-dependent10.1038/nnano.2008.30 ↗
10. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis10.1073/pnas.1006507107 ↗
11. Gold nanoparticles to improve HIV drug delivery10.4155/fmc.15.57 ↗
12. Kinetic evidence for protein clustering at a surface10.1103/PhysRevE.50.5072 ↗
13. Time evolution of the nanoparticle protein corona10.1021/nn901372t ↗
14. Protein adsorption on solid surfaces10.1016/S0958-1669(96)80098-X ↗
15. Biomolecular coronas provide the biological identity of nanosized materials10.1038/nnano.2012.207 ↗
16. Characterizing self-assembled monolayers on gold nanoparticles10.1021/acs.bioconjchem.6b00587 ↗
17. Effect of absorbed proteins on the wettability of hydrophilic and hydrophobic solids10.1038/196476a0 ↗
18. Domain formation and conformational changes in gold nanoparticle conjugates studied using DPD simulations10.1021/acs.langmuir.7b03318 ↗
19. Spontaneous assembly of subnanometre-ordered domains in the ligand shell of monolayer-protected nanoparticles10.1038/nmat1116 ↗
20. Entropy-mediated patterning of surfactant-coated nanoparticles and surfaces10.1103/PhysRevLett.99.226106 ↗
21. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma10.1128/JVI.06547-11 ↗
22. Size-dependent protein-nanoparticle interactions in citrate-stabilized gold nanoparticles: the emergence of the protein corona10.1021/acs.bioconjchem.6b00575 ↗
23. Electrostatic titrations reveal surface compositions of mixed, on-nanoparticle monolayers comprising positively and negatively charged ligands10.1021/acs.jpcc.5b12599 ↗
24. Gold nanoparticles can induce the formation of protein-based aggregates at physiological pH10.1021/nl803054h ↗
25. Conserved effects and altered trafficking of Cetuximab antibodies conjugated to gold nanoparticles with precise control of their number and orientation10.1039/C7NR00947J ↗
26. How antibody surface coverage on nanoparticles determines the activity and kinetics of antigen capturing for biosensing10.1021/ac501536z ↗
27. Characterization of ligand shell for mixed-ligand coated gold nanoparticles10.1021/acs.accounts.7b00165 ↗
28. The role of PEG conformation in mixed layers: from protein corona substrate to steric stabilization avoiding protein adsorption
29. Stripy nanoparticles revisited10.1002/smll.201001465 ↗
30. Response to “Critical assessment of the evidence for striped nanoparticles”10.1371/journal.pone.0135594 ↗
31. Supramolecular domains in mixed peptide self-assembled monolayers on gold nanoparticles10.1002/cbic.200800326 ↗
32. Assessment of the morphology of mixed SAMs on Au nanoparticles using a fluorescent probe10.1039/C0CC02260H ↗
33. Comparison of four functionalization methods of gold nanoparticles for enhancing the enzyme-linked immunosorbent assay (ELISA)10.3762/bjnano.8.27 ↗
34. Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine10.1021/jp057170o ↗
35. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum10.1128/JVI.00171-11 ↗
36. Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity10.1016/j.clim.2009.09.006 ↗
37. Maximizing the immunological output of the cervicovaginal explant model10.1016/j.jim.2018.06.005 ↗
38. Defining total-body AIDS-virus burden with implications for curative strategies10.1038/nm.4411 ↗
39. In vivo studies investigating biodistribution of nanoparticle-encapsulated rhodamine B delivered via dissolving microneedles10.1016/j.jconrel.2017.04.022 ↗
40. Nanotechnology approaches to eradicating HIV reservoirs10.1016/j.ejpb.2018.06.002 ↗
41. Nanoparticle-based immunoengineered approaches for combating HIV10.3389/fimmu.2020.00789 ↗
42. The role of Fc receptors in HIV prevention and therapy10.1111/imr.12339 ↗
43. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs10.4049/jimmunol.1200501 ↗
44. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection10.1128/JVI.02194-14 ↗
45. Up on the tightrope: natural killer cell activation and inhibition10.1038/ni1581 ↗
46. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion10.1182/blood-2005-04-1351 ↗
47. Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity10.4049/jimmunol.168.11.5764 ↗
48. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment10.4049/jimmunol.179.4.2642 ↗
49. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation10.4049/jimmunol.1200458 ↗
50. PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function10.1007/s12274-020-2684-1 ↗
51. Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells10.1016/j.biomaterials.2016.11.048 ↗
52. Optically induced cell fusion using bispecific nanoparticles10.1002/smll.201300696 ↗
53. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition10.1158/1078-0432.CCR-13-0505 ↗
54. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production10.1158/1535-7163.MCT-12-0692 ↗
55. HIV rebounds from latently infected cells, rather than from continuing low-level replication10.1073/pnas.0804192105 ↗
56. Monkeying around: using non-human primate models to study NK cell biology in HIV infections10.3389/fimmu.2019.01124 ↗
57. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial10.1016/S2352-3018(14)70014-1 ↗
58. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy10.1038/nature11286 ↗
59. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy
60. Immune-correlates analysis of an HIV-1 vaccine efficacy trial10.1056/NEJMoa1113425 ↗
61. Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat10.1128/JVI.01484-15 ↗
62. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies10.1128/jvi.68.12.8350-8364.1994 ↗
63. Paring down HIV Env: design and crystal structure of a stabilized inner domain of HIV-1 gp120 displaying a major ADCC target of the A32 region10.1016/j.str.2016.03.005 ↗
64. Survivors remorse: antibody-mediated protection against HIV-110.1111/imr.12510 ↗
65. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations10.1038/nature14053 ↗
66. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line10.4049/jimmunol.134.2.971 ↗
67. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor10.1128/JVI.73.11.8966-8974.1999 ↗
68. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone10.4049/jimmunol.142.2.431 ↗
69. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone10.1073/pnas.86.7.2365 ↗
70. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop10.1128/jvi.67.8.4785-4796.1993 ↗
71. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding10.1128/jvi.69.9.5723-5733.1995 ↗
72. Kinetically controlled seeded growth synthesis of citrate-stabilized gold nanoparticles of up to 200 nm: size focusing versus Ostwald ripening10.1021/la201938u ↗
73. Size and shape of protein molecules at the nanometer level determined by sedimentation, gel filtration, and electron microscopy10.1007/s12575-009-9008-x ↗
74. The MARTINI coarse-grained force field: extension to proteins10.1021/ct700324x ↗
75. Exploiting seeding of random number generators for efficient domain decomposition parallelization of dissipative particle dynamics10.1016/j.cpc.2012.12.003 ↗
76. Dissipative particle dynamics: effects of parameterization and thermostating schemes on rheology10.1080/1539445X.2015.1022898 ↗
77. Chitosan as a capping agent: Insights on the stabilization of gold nanoparticles10.1016/j.carbpol.2018.12.046 ↗
78. A study on the molecular existing interactions in nanoherbicides: a chitooligosaccharide/tripolyphosphate kloaded with paraquat case10.1016/j.colsurfa.2018.11.033 ↗
79. Molecular simulation of the effect of cholesterol on lipid-mediated protein-protein interactions10.1016/j.bpj.2010.09.030 ↗
80. Simulation studies of protein-induced bilayer deformations, and lipid-induced protein tilting, on a mesoscopic model for lipid bilayers with embedded proteins10.1529/biophysj.104.050849 ↗
81. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity10.1016/j.jim.2005.09.018 ↗
82. Use of human tissue explants to study human infectious agents10.1038/nprot.2008.245 ↗